Company intelligence / Profile preview

MBD Co., Ltd.

Suwon-si, Gyeonggi-do, South Koreapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

MBD has developed a proprietary three-dimensional cell culture chip/platform specialized in predicting the efficacy and toxicity of drugs, with a focus on anticancer applications. The company’s pipeline includes preclinical candidates targeting cancer, NASH, and metabolic diseases. No late-stage or commercialized products are reported as of June 2025.

Therapeutic areas: OncologyMetabolic DisordersGastroenterology
Modalities: Small moleculePeptidesNot specified for all programs; platform supports multiple modalities via drug testing
Industry: Biotech

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on MBD Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBD Co., Ltd..

Explore the full profile